Opko méxico

Financial Times Close. Search the FT Search. Show more World link World.

Harga Tertinggi Hari Ini. Q2 Q3 Q4 Q1

Opko méxico

.

Search the FT Search. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, opko méxico, and vitamin D insufficiency; OPK, an orally administered selective androgen receptor modulator; OPK, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase Opko méxico trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc, opko méxico.

.

The launch in Mexico follows the U. The 4Kscore provides a patient with his own individualized risk for aggressive prostate cancer. The test was developed and validated by OPKO in a 1, patient blinded, prospective study in the United States in Sanoj Punnen, of the University of Miami. In Mexico, prostate cancer is the most common cause of cancer death in males with 5, deaths recorded in According to the World Health Organization, prostate cancer is the second most common cancer in men worldwide, with over 1. In countries like the U. However, most of the prostate cancers that are now detected are an indolent, non-life threatening form of the disease.

Opko méxico

Ver el Informe Ampliado. Acceda al Informe ampliado de esta empresa:. Esta empresa se ha consultado en eInforma un total de 2.

Gordon ryan sonny

In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisions. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK, an orally administered selective androgen receptor modulator; OPK, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. Show more Companies link Companies. Ini bukan rekomendasi investasi. Health Care Medical Equipment and Services. Cancel Continue. Save Clear. Short selling activity Low. Show more Markets link Markets. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others.

La empresa es una Sociedad Limitada. Ha subido del

Q3 All content on FT. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK, an orally administered selective androgen receptor modulator; OPK, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. Search the FT Search. All rights reserved. Harga Tertinggi Hari Ini. Average volume Health Care Medical Equipment and Services. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. Financial Times Close.